ProMetic announces Octapharma publication of PRDT'S prion removal resin in Octaplas(R) manufacturing process at 30th Internation

MONTREAL, Canada and CAMBRIDGE, United Kingdom , June 10 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that Octapharma AG ("Octapharma"), one of the World's leading plasma fractionators and manufacturer of...


About Pathogen Removal and Diagnostic Technologies Inc.

Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") is a joint venture established in April 2002 by The American Red Cross and ProMetic Life Sciences Inc., and allows for the exchange of technology and knowledge between the two organizations. PRDT's main goal is to develop products and devices to remove and detect different pathogens from biological sources. This research augments work that ProMetic, the American Red Cross and PRDT's scientific founders have been conducting independently for many years.

About ProMetic BioSciences Ltd

Using its unique and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and manufacture of robust affinity separation materials which provide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured according to a strict quality system based on good manufacturing practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle of Man , which completed a (pnds stlg)1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, UK.

About Octapharma AG

Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality human proteins. The Company has grown to 2,500 employees in 27 countries since its founding in 1983. Octapharma owns five modern, state-of-the-art production facilities in Austria , France , Sweden , Mexico and Germany . Sales turnover in 2007 exceeded Euro 752 million. Octapharma continues to grow and invest heavily in the future. Profits are mainly channeled into R&D and further improvements and expansion of Production. In the highly demanding market of life-saving plasma products, Company success is only possible through reliable product quality and a proven safety record.

About Octaplas(R)

Octaplas(R) is a pharmaceutical quality human coagulation active plasma for transfusion. Besides being solvent/detergent virus inactivated, the product is standardized, which promotes a better planning and monitoring of treatment. Furthermore, the removal of all residual blood cells and neutralization of both allergens and antibodies against leukocytes render this medicinal product virtually free from causing allergic reactions and the risk for transfusion-related acute lung injuries ("TRALI"), being the most common cause of death in transfusion medicine, has been abolished. Octaplas(R) increases through these multiple favourable features the level of efficacy and security in transfusion medicine, both representing the foundation in all medical care, and reduces costs. The product is used to treat complex and isolated coagulation disorders - both congenital and acquired - where no specific coagulation factor concentrate is available, and thrombotic thrombocytopenic purpura ("TTP") - usually in conjunction with plasma exchange. Octaplas(R) is fully licensed in 29 countries worldwide, and roughly 6 million bags have been used successfully to treat approximately 2 million patients around the world since 1991.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal ( Canada ), ProMetic has R&D facilities in the UK, the US and Canada , manufacturing facilities in the UK and business development activities in the US, Europe , Asia and in the Middle-East .